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A B S T R A C T
In this paper legal prerequisites for vaccine licensure in Croatia are discussed. The Croatian legislation concerning
vaccine licensing, marketing authorisation and utilization is reviewed. The procedures for including a vaccine into the
Mandatory Childhood Vaccination Programme are also discussed with focus on Human papillomavirus (HPV) vaccines.
Non-obligatory vaccination recommendations are given when according to professional opinion; vaccination is benefi-
cial for the vaccinee. There is little doubt that HPV vaccines should be recommended for preadolescent girls in Croatia.
However, reaching a decision on its possible introduction into the Childhood Vaccination Programme will require care-
ful consideration of the larger picture and a comparison of the cost-effectiveness of a mandatory vaccination against
other competing public health priorities.
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Introduction
The first prerequisite for a vaccine to be legally used
in Croatia is licensure. The Agency for Medicinal Prod-
ucts and Medical Devices (AMPMD) is responsible for
the licensing procedure and for marketing authorization
of vaccines1. However, it is very important to understand
that licensing and marketing authorization only guaran-
tee the quality, safety and efficacy of vaccines but this
does not determine the way a vaccine will be used.
Each lot of vaccine regardless of the manufacturer is
subject to quality control performed by the AMPMD, Di-
vision for Immunological Medicinal Products. Further,
the AMPMD undertakes a variety of other tasks includ-
ing postmarketing surveillance and this is done in collab-
oration with the Croatian National Institute of Public
Health which is responsible for surveillance of adverse
events following immunization. Based on this surveil-
lance, the AMPMD can request that the manufacturer
review and change the summary of product characteris-
tics, as well as the prescribing information.
The way a vaccine will be used depends on a number
of epidemiological, regulatory and financial factors. Vac-
cines may be mandatory for the entire eligible population
such as specific birth cohorts according to the Childhood
Vaccination Programme2, or for specific at-risk groups
such as hepatitis B vaccination for health care workers.
Then, there are vaccines that are recommended for spe-
cific groups such as typhoid fever vaccination for travel-
lers to endemic areas and influenza vaccination for the
elderly, health care workers and chronically-ill patients.
Mandatory Vaccinations
Each year, the Minister of Health announces the
Childhood Vaccination Programme (»the Programme«)
based on the recommendation from the Croatian Insti-
tute of Public Health (CIPH). The declaration of manda-
tory vaccination or the provision of free-of-charge vac-
cines is regulated by health care legislation, primarily
the Act on the Protection of the Population from Infec-
tious Diseases, which is further elaborated by the imple-
menting provisions that are issued by the Minister of
Health3,4. Mandatory vaccinations that are covered by
117
Received for publication January 31, 2007
	
	
/

	
 !" 
#
 
 $  
the Childhood Vaccination Programme are obligatory for
all in the defined target population because it is in the in-
terest of the community to have all its members / citizens
vaccinated, as well as being in the interest of the individ-
ual vaccinee. All mandatory vaccinations according to
the Programme are free of charge for the vaccinee, be-
cause the vaccines are purchased and vaccination is re-
imbursed to primary health care physicians by the Cro-
atian Health Insurance Institute. The current Childhood
Vaccination Programme is presented in Table 1.
Mandatory vaccination carries with it the responsibil-
ity of the government to secure safe and effective vac-
cines and to organise the health care system in such a
way that it makes vaccination accessible to all within the
designated target population. This is also regulated by
law, primarily the Health Care Act, the Act on the Pro-
tection of the Population from Infectious Diseases (noted
above), as well as various bylaws and ordinances arising
from these acts5. According to these documents, it is the
duty of primary health care providers to vaccinate pre-
school children according to the Programme. Newborns
are vaccinated in the maternity wards, while elementary
school pupils are vaccinated at school by the school medi-
cal service that is affiliated to the County Institutes of
Public Health.
As you will see, mandatory vaccination involves an
enormous commitment on the part of the community, in-
stitutions and individuals so the decision to include a vac-
cine into the Programme or not must be based on solid sci-
entific evidence and the highest professional expertise.
The Croatian Institute of Public Health (CIPH) is the
institution responsible for designing the Childhood Vacci-
nation Programme in Croatia. In collaboration with the
relevant partners (representatives of paediatric associati-
ons, school health associations, epidemiologist associations,
family doctors, etc.), the CIPH analyses the epidemiolo-
gical situation regarding vaccine-preventable diseases,
the performance of the proposed vaccination programme
and all suggestions relevant to the Programme to de-
velop and present a recommendation to the Minister. In
certain instances, public opinion is taken into account in
the decision-making process even if it is at odds with the
scientific evidence and professional knowledge.
There are also a number of vaccinations which are man-
datory for specific groups, e.g. hepatitis B (HBV) vaccina-
tion for health-care workers and for sexual partners of
HBV carriers, then prophylaxis for persons exposed to ra-
bies; these vaccines are free of charge for individuals and
reimbursed by the Croatian Health Insurance Institute.
Recommended Vaccination
Non-obligatory vaccination recommendations are those
considered to be of interest for the individual but not to
the whole community, and these can be either paid for by
public Health Insurance or the individual. For example,
influenza vaccination for health-care workers, the el-
derly and chronically-ill patients, pneumococcal vaccina-
tion for asplenic patients and the elderly in nursery
homes, etc. are examples of vaccinations that are recom-
mended and paid for by public Health Insurance. Then,
all vaccinations recommended to travellers to prevent
diseases that are endemic in the countries they are going
to such as cholera, meningococcal meningitis, yellow fe-
ver or hepatitis A are paid for by the vaccinee. The same
applies to tick-borne encephalitis vaccine, which is rec-
ommended for persons exposed to ticks in endemic areas,
either professionally or recreationally.
HPV Vaccination
As far as Human papillomavirus (HPV) vaccine is
concerned, as soon as the vaccine is licensed and the
batch control is finished, the vaccine will receive market-
ing authorization and can be used in Croatia. Then, rec-
ommendations for the use of vaccination will be issued by
professional medical associations, e.g. gynaecology, pae-
diatrics or epidemiology associations, or other non-gov-
ernmental associations. Whether it will be reimbursed or
not depends on the Health Insurance Institute. Any of
the associations which issue recommendations can sug-
gest the reimbursement of vaccination by the Health In-
surance Institute or request the Ministry of Health to
initiate the process for covering expenses by the Health
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TABLE 1
CHILDHOOD VACCINATION PROGRAMME IN CROATIA
FOR YEAR 2007
Age Vaccine
Birth* BCG, Hepatitis B
2 months Hib, Hepatitis B
3 months DTP, IPV
4 months DTP, OPV, Hib
6 months DTP, OPV, Hib, Hepatitis B
12–18 months MMR, DTP, OPV, Hib
3 years DTP
6 years MMR, Td, OPV
12 years Hepatitis B **
13 years PPD, BCG***
14 years Td, OPV
19 years TT
60 years TT
BCG – Bacillus Calmette-Guerin, Hib – Haemophilus influenzae
type B, DTP – Diphtheria, tetanus, pertusis, IPV – Inactivated
polio vaccine, OPV – Oral polio vaccine, MMR – Measles, mumps,
rubella, PPD – Purified protein derivative testing, Td – Tetanus,
diphtheria, adult formulation, TT – Tetanus toxoid, * Newborns
to HBsAg positive mothers receive HBIG at birth together with
the first dose of hepatitis B vaccine, which is continued accord-
ing to a 0, 1, 2, 12 scheme, ** Three doses of hepatitis B vaccine
according to a 0, 1, 6 scheme. Vaccination at the age of 12 will be
discontinued when children vaccinated as newborns reach this
age, *** BCG revaccination is administered only to PPD nega-
tive children
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Insurance Institute. In both cases, the Health Insurance
Institute establishes a committee of the relevant medical
experts and eventually decides whether the Health In-
surance Institute will cover the expenses or not.
The vaccination strategy that is anticipated to have
the greatest impact on the incidence of cervical carci-
noma in the future would involve at least universal vacci-
nation of preadolescent girls6. In Croatia, this means in-
troducing the vaccine into the mandatory Childhood
Vaccination Programme.
Although the public health burden of cervical carci-
noma in Croatia is well-known, together with the general
epidemiology of HPV infection and the general charac-
teristics of available vaccines, there are still uncertain-
ties which must be clarified before considering the intro-
duction of HPV vaccine into the Programme.
The reduction of precancerous and invasive cervical
lesions achieved by vaccination with reasonably high cov-
erage rates is anticipated to be substantial, but not
enough to eliminate the need for cervical screening6,7. In
order to calculate how substantial this reduction of pre-
cancerous lesions and cancer will be, a systematic review
of available information on the prevalence of HPV types
in our population is necessary. Then, this will need to be
compared to the impact that could be achieved through
improvements to the cervical screening system. Never-
theless, the potential of HPV vaccines to prevent precan-
cerous lesions caused by HPV types included in the vaccine
would appear to favour vaccine introduction regardless
of the reductions in cancer that could be achieved by im-
provements to screening.
A characteristic of the HPV vaccine that could be an
obstacle to the wide acceptance of the vaccine in public as
well as in the professional community is the fact that a
significant impact on the burden of disease can not be ex-
pected within 20–30 years of the introduction of the vac-
cination into the Programme, provided always that high
coverage rates would be achieved and maintained contin-
uously. And finally, the price of introducing this vaccine
into the Programme is an important issue. In case it
would be established that vaccination would achieve
better results in reducing cervical cancerous lesions than
alternative interventions (e.g. enhanced screening), the
cost-effectiveness would have to be assessed against
other interventions in the health care system, waiting to
be implemented or improved. Since the health budget is
a single source, money for screening programmes, paper
towels or antibiotics all comes from the same source as
the funds for vaccination, there are numerous needs
competing with each other for the funds.
So far, the introduction of vaccines into the Pro-
gramme was never limited by the health care budget,
mostly due to the fact that it was clear the vaccines (at
their given prices) were the most cost-effective interven-
tions. However, it is expected that one dose of HPV vac-
cine would cost about 100 Euros and therefore, introduc-
ing this vaccine into the Programme to vaccinate only
one birth cohort of girls (e.g. 11-year-old girls) would
raise the annual cost of the Programme by 130% (the
HPV vaccine would cost about 6.7 million Euros which is
30% more than all the other vaccines used in the Pro-
gramme at the moment 5.1 million Euros8).
Conclusion
The HPV vaccine will soon be licensed in Croatia and
will have an important role in the prevention of cervical
cancer in this country. Immediately after licensure physi-
cians will be able to use it on individual, patient-pay ba-
sis. In order to ensure reimbursement of the vaccine by
the Croatian Health Insurance Institute, a request would
need to be issued and an expert committee would then
decide if the request should be accepted.
Regardless of the reimbursement policy for recom-
mended vaccinations, no effect on the public health bur-
den of cervical cancer can be expected unless vaccination
is implemented to the whole target population within a
well designed vaccination programme. This could be
achieved by introducing HPV vaccination into the man-
datory Childhood Vaccination Programme.
Still, much information must be gathered in order to
assess the potential public health benefit of this vaccine
in Croatia (type specific epidemiology of HPV in Croatia,
potential of improved screening for cervical cancer in
Croatia, etc.). From the perspective of an institution re-
sponsible for the introduction of new vaccines into the
Childhood Vaccination Programme and the allocation of
considerable amounts of public funding into one specific
intervention, we believe that these associations advocat-
ing introduction of a new vaccine should make every ef-
fort to demonstrate this is the best available option.
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ZAKONSKA REGULATIVA VEZANO UZ CJEPIVA U HRVATSKOJ
S A @ E T A K
U ovom ~lanku raspravlja se o legislativi koja mora biti udovoljena da bi se cjepiva koristila u Hrvatskoj. Kori{teni su
zakoni i pravilnici kojima se regulira registracija, pu{tanje lijeka u promet, te na~in kori{tenja cjepiva. Postupci za
uklju~ivanje cjepiva u Program obveznih cijepljenja su tako|er prodiskutirani, s naglaskom na cjepivo protiv humanog
papilomavirusa (HPV). Preporuke za cijepljenja koja nisu obvezna se izdaju na temelju stru~nog stava da je cijepljenje
korisno za pojedinca. Nema sumnje da se cijepljenje protiv HPV-a mo`e preporu~iti djevoj~icama u preadolescentnoj
dobi. Me|utim, da bi se donijela odluka o uvo|enju cjepiva u Program obveznih cijepljenja potrebno je sa razli~itih
medicinskih stajali{ta razmotriti uvo|enje cijepljenja u odnosu na druge javnozdravstvene prioritete koji se nadme}u za
ista sredstva.
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